wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q39515202-01E5F3EC-B6E0-4A00-BEAA-A0591DB45052
Q39515202-01E5F3EC-B6E0-4A00-BEAA-A0591DB45052
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39515202-01E5F3EC-B6E0-4A00-BEAA-A0591DB45052
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
P2860
Q39515202-01E5F3EC-B6E0-4A00-BEAA-A0591DB45052
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39515202-01E5F3EC-B6E0-4A00-BEAA-A0591DB45052
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
cead3ce6e3b11d4cf7b0b7fa0c53f4720e4fcf0a
P2860
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.